CRAMS, APIs - Consistency Breeding Stability: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Indian pharma companies are looking at a sustainable growth opportunity in the coming decade as the lack of differentiation in generics has chipped away at margins due to increased competition.
While companies with a large U.S. generics exposure are looking at niche opportunities like complex generics/specialty drugs, contract research and manufacturing services for active pharma ingredient/formulation has emerged as a successful opportunity for companies with a sound technical, manufacturing, and regulatory expertise.
The branded domestic formulation space remains a high return ratio segment, with a moderation in growth, excluding Covid-19, due to the reduced burden of acute diseases.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.